Global pharma major Lupin Limited (Lupin) announced the launch of Emtricitabine and Tenofovir Disoproxil Fumarate tablets 200 mg/300 mg, having received an approval from the United States Food and Drug Administration (FDA).
Emtricitabine and Tenofovir Disoproxil Fumarate tablets 200 mg/300 mg, are the generic equivalent of Truvada tablets 200 mg/300 mg, of Gilead Sciences, Inc., and indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US$2.1 billion in the US.